Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.48 |
| ▸ | PPIB | P23284 | 1/20 | 0.48 |
| ▸ | PPIG | Q13427 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.48 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064471 | 1.00 | PPID (0.48) | PPIDPPIBPPIGRIPK1SCD5 | |
| SCHEMBL28532906 | 0.83 | PPID (0.53) | PPIDPPIBPPIGRIPK1SCD5 | |
| SCHEMBL2330771 | 0.82 | PPID (0.52) | PPIDPPIBPPIGRIPK1SCD5 | |
| SCHEMBL28535098 | 0.81 | RIPK1 (0.46) | RIPK1TERTRBP4HSP90AA1HSP90AB1 | |
| SCHEMBL28535096 | 0.81 | RIPK1 (0.46) | RIPK1TERTRBP4HSP90AA1HSP90AB1 | |
| SCHEMBL31525016 | 0.80 | RIPK1 (0.45) | RIPK1TERTRBP4HSP90AA1HSP90AB1 | |
| SCHEMBL1576663 | 0.80 | RIPK1 (0.73) | RIPK1SCD5HSP90AA1HSP90AB1 | |
| SCHEMBL3312132 | 0.78 | NR1H2 (0.57) | PPIDPPIBPPIGRIPK1SCD5 | |
| SCHEMBL3313724 | 0.78 | NR1H2 (0.57) | PPIDPPIBPPIGRIPK1SCD5 | |
| SCHEMBL2325712 | 0.78 | NR1H2 (0.57) | PPIDPPIBPPIGRIPK1SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | PPID 762/4885PPIB 389/4885PPIG 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.